BIONIM
NIMODIPINE · by HORIZON
Composition
Tab 30 mg: Nimodipine 30 mg. Inf: Per ml: Nimodipine 0.2 mg; 50 ml soln.
Indications & Dosage
Prevention of ischaemic neurological deficits following subarachnoid haemorrhage: ORAL: Adults: 2 tab four hrly starting within 4 days of subarachnoid haemorrhage and continue for 21 days. Treatment of neurological deficits following subarachnoid haemorrhage: BY IV INF: Adults: 1 mg/hr, by IV INF for first 2 hr, then 2 mg/hr for minimum 5 days, max 14 days. Patients weighing under 70 kg or with unstable BP, start on 0.5 mg/hr. Children: Not recommended.
Administration
Via drip tubing in D5W or NS or Compound sodium lactate. Not to be added to infusion container, ad-minister via an infusion pump through a Y-piece into a central catheter.
Compatibility
Incompatible with polyvinyl chloride giving sets or containers.
Stability
Nimodipine infusion solution must not be mixed with other drugs. It is advisable to continue administration of nimodipine infusion solution during anesthesia, surgery, and angiography. Protect infusion from light.
Precautions
Cerebral oedema, raised intracranial pressure, renal impairment, cirrhosis, hypotension (Infusion only). Monitor BP Nimotop infusion is incompatible with PVC.
Interactions
Beta-blockers, other calcium antagonists, anti-convulsants, cimetidine.
Pregnancy
Caution advised
Lactation
Not recommended
Side Effects
Hypotension, flushing, headache, changes in heart rate, GI upset, transient rise in liver enzymes may occur with infusion.